Cited by 38Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration MechanismsDementia and Cognitive Impairment Research

Vulnerability of calbindin, calretinin and parvalbumin in a transgenic/knock-in APPswe/PS1dE9 mouse model of Alzheimer disease together with disruption of hippocampal neurogenesis

Verdaguer, Ester, Brox, Susana, Petrov, Dmitry, Olloquequi, Jordi, Romero, Rafael, de Lemos, M. Luisa, Camins, Antoni, Auladell, Carme·2015·Experimental Gerontology

Abstract

The pathogenesis of Alzheimer disease (AD) is characterized by accumulation of β-amyloid protein in the brain (in both soluble and insoluble forms) and by the presence of intracellular neurofibrillary tangles (NFTs), leading to neurotoxicity. The exact mechanisms whereby Aβ triggers brain alterations are unclear. However, accumulating evidence suggests that a deregulation of Ca(2+) signaling may play a major role in disease progression. Calcium-buffering proteins, including calbindin-D28K (CB), calretinin (CR) and parvalbumin (PV), may offer neuroprotection by maintaining calcium homeostasis. Although marked reductions in these proteins have been observed in the brains of mice and humans with AD, their contribution to AD pathology remains unclear. The aim of the present study was to analyze distribution patterns of CB(+,) CR(+) and PV(+) interneurons in different areas of the hippocampus, a brain region that is severely affected in AD. A transgenic knock-in APPswe/PS1dE9 mouse model of familial AD was used. The data were obtained from the brains of 3- and 12-month-old animals. These ages roughly correspond to an early mature adult (prior to clinical manifestations) and a late middle-age (clinical symptoms readily detectable) phase in human AD patients. Immunostaining revealed increases in CB and PV immunoreactivity (IR) in the hippocampus of 3-month-old transgenic mice, compared to wild-type animals. Possibly, these proteins are upregulated in an attempt to control cellular homeostasis and synaptic plasticity. However, the pattern of CB-IR was reversed in 12-month-old animals, potentially indicating a loss of cellular capacity to respond to pathophysiological processes. In addition, at this age, a noticeable increase in PV-IR was observed, suggesting the presence of hippocampal network hyperactivity in older AD-like mice. Our results indicate that CaBP(+) neuronal subpopulations play a role in adult neurogenesis and in AD pathology, particularly at early disease stages, suggesting that these neurons may serve as potential predictors of future AD in non-demented individuals.

Integrity signals

Registry

Crossref · 10.1016/j.exger.2015.06.013

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Hippocampal PV immunoreactivity is increased in another mouse model of Alzheimer's disease.

    “For example, decreases in the number of PV-INs in the hippocampus were observed in two mouse models of AD [33,34], while an increase in hippocampal PV immunoreactivity was observed in another [35], and no change in the number of hippocampal PV-positive interneurons was observed in yet another model [36].”

    From Parvalbumin interneuron vulnerability and brain disorders (2021) · cites this paper as [35]

The citation lists haven’t been fetched yet

References 57 · Cited by 38

Authors
Verdaguer, E., Brox, S., Petrov, D., Olloquequi, J., Romero, R., de Lemos, M. L., Camins, A., & Auladell, C.
Affiliations
  • Universitat de Barcelona (ES)
  • Biomedical Research Networking Center on Neurodegenerative Diseases (ES)
  • Universidad Autónoma de Chile (CL)
Corresponding author
Auladell, Carme
Venue
Experimental Gerontology
Publisher
Elsevier BV
Published
2015-09
Volume
69
Pages
176-188
ISSN
0531-5565 (ISSN-L)
OpenAlex
W926581725
Cited by
38
References
57
Citations by year
2026: 1 · 2024: 4 · 2023: 1 · 2022: 3 · 2021: 3 · 2020: 9 · 2019: 7 · 2018: 2 · 2017: 3 · 2016: 5
FWCI
2.46
Type
journal article
Language
en
Open access
closed
Locations
  • Experimental Gerontology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Generalitat de Catalunya (BFU2010/19119/BFI, BFU2010-19119)
  • Spanish Ministerio de Ciencia e Innovación (MICINN) (SAF2011-23631)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
Alzheimer's disease, calbindin-D28k, calretinin, parvalbumin, calcium-binding proteins, calcium homeostasis, calcium signaling, APPswe/PS1dE9 transgenic mice, familial Alzheimer's disease, hippocampus, hippocampal interneurons, adult neurogenesis, amyloid-beta, neurofibrillary tangles, neuroprotection, early-stage disease, biomarkers
MeSH terms
Alzheimer Disease, Animals, Disease Models, Animal, Hippocampus, Mice, Transgenic, Neural Conduction, Neuronal Plasticity, Parvalbumins, Neurofibrillary Tangles, Disease Progression, Mice, Neurogenesis, Calbindins, Calbindin 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review